Cycle Pharmaceuticals to launch TASCENSO ODT® (fingolimod) in US in Q1 2023

By |2022-11-30T11:21:25+00:00November 1st, 2022|News|

Tony Cates joins Cycle Group Holdings Board of Directors

By |2022-11-30T11:31:47+00:00October 6th, 2021|News, Nityr|

Cycle Pharmaceuticals launches SAJAZIR TM (icatibant) Injection, a new treatment option in Hereditary Angioedema (HAE)

By |2022-11-30T11:32:04+00:00September 28th, 2021|News, Nityr|

Cycle Pharmaceuticals Launches Cycle Vita™, a dedicated support platform for rare disease patients

By |2022-11-30T11:32:18+00:00September 10th, 2021|News, Nityr|

Cycle Pharmaceuticals appoints Denise Moody as Chief Operating Officer

By |2021-06-28T11:44:17+01:00June 28th, 2021|Corporate, News|

Cycle Pharmaceuticals appoints Steve McCue as Chief Financial Officer

By |2022-11-30T11:33:08+00:00May 25th, 2021|Corporate, News|

Dr Alejandra Bruna joins Cycle Group Holdings Board of Directors

By |2022-11-30T11:33:22+00:00April 29th, 2021|News, Nityr|

NITYR (nitisinone) Tablets for Tyrosinaemia Type 1 receives Marketing Authorization in New Zealand

By |2022-11-30T11:33:41+00:00March 15th, 2021|News, Nityr|

Cycle Announces the Appointment of Angela Kurtz as Clinical Metabolic Director to lead its newly created Clinical Metabolic Department

By |2021-05-17T18:52:30+01:00December 2nd, 2020|Generics, News|

Cycle Pharmaceuticals’ NITYR® (nitisinone) Tablets Receives Marketing Authorization in Israel

By |2021-05-17T18:52:30+01:00October 19th, 2020|News, Nityr|
Go to Top